On November 3rd, 2017, Virginia Contract Research Organization Co., Ltd. (VCRO) was granted a Phase II IND clinical go from the US FDA in a new speed record of 23 days after initial submission for Parkinson’s disease dementia (PDD) treatment. This medicine acts via a novel mechanism, neuro-protective and neurogenesis, potentially bringing new hope to PDD patients. The IND package was prepared and submitted in common technical document (CTD) format by VCRO.
Congratulation! A Phase II IND of the Parkinson’s disease dementia treatment was granted by the US FDA.
On November 3rd, 2017, Virginia Contract Research Organization Co., Ltd. (VCRO) was granted a Phase II IND clinical go from the US FDA in a new speed record of 23 days after initial submission for Parkinson’s disease dementia (PDD) treatment. This medicine acts via a novel mechanism, neuro-protective and neurogenesis, potentially bringing new hope to…